Journal article
Treatment of intracranial aneurysms with the Enterprise stent: a multicenter registry
Journal of neurosurgery, v 110(1), pp 35-39
01 Jan 2009
PMID: 18976057
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Object. The development of self-expanding stents dedicated to intracranial use has significantly widened the applicability of endovascular therapy to many intracranial aneurysms that Would otherwise have been Untreatable by endovascular techniques. Recent Food and Drug Administration approval of the Enterprise Vascular Reconstruction Device and Delivery System (Cordis) has added a new option for self-expanding stent-assisted intracranial aneurysm coiling.
Methods. The authors established a collaborative registry across multiple institutions to rapidly provide large-volume results regarding initial experience in using the Enterprise in real-world practice. Ten institutions (University at Buffalo, Thomas Jefferson University, University of Florida, Cleveland Clinic, Northwestern University, West Virginia University, University of Puerto Rico, Albany Medical Center Hospital, the Neurological Institute of Savannah, and the Barrow Neurological Institute) have provided consecutive data regarding their initial experience with the Enterprise.
Results. In total, 141 patients (119 women) with 142 aneurysms underwent 143 attempted stent deployments. The use of Enterprise assistance with aneurysm coiling was associated with a 76% rate of >= 90% Occlusion. An inability to navigate or deploy the stent wits experienced in 3% of cases, as well as it 2% occurrence of inaccurate deployment. Procedural data demonstrated a 6% temporary morbidity, 2.8% permanent morbidity, and 2% mortality (0.8% unruptured, 12% ruptured).
Conclusions. The authors report initial results of the largest series to date in using the Enterprise for intracranial aneurysm treatment. The Enterprise is associated with it high rate of successful navigation and low Occurrence of inaccurate stent deployment. The overall morbidity and mortality rates were low: however, caution should be exercised when considering Enterprise deployment in patients with subarachnoid hemorrhage as the authors' experience demonstrated it high rate of associated hemorrhagic complications leading to death. (DOI: 10.3171/2008.7.JNS08322)
Metrics
Details
- Title
- Treatment of intracranial aneurysms with the Enterprise stent: a multicenter registry
- Creators
- J. Mocco - ToshibaKenneth V. Snyder - University at Buffalo, State University of New YorkFelipe C. Albuquerque - Barrow Neurological InstituteBernard R. Bendok - Neurological SurgeryAlan S. Boulos - Albany Medical Center HospitalJeffrey S. Carpenter - West Virginia UniversityDavid J. Fiorella - Cleveland ClinicBrian L. Hoti - Univ Florida, Coll Med Gainesville, Dept Neurosurg, Gainesville, FL 32611 USAJay U. Howington - The Neurological InstituteBrian T. Jankowitz - University of Pittsburgh Medical CenterKenneth M. Liebman - Thomas Jefferson UniversityAnsaar T. Rai - West Virginia UniversityRafael Rodriguez-Mercado - University of Puerto Rico SystemAdnan H. Siddiqui - University at Buffalo, State University of New YorkErol Veznedaroglu - Thomas Jefferson UniversityL. Nelson Hopkins - University at Buffalo, State University of New YorkElad I. Levy - University at Buffalo, State University of New York
- Publication Details
- Journal of neurosurgery, v 110(1), pp 35-39
- Publisher
- Amer Assoc Neurological Surgeons
- Number of pages
- 5
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Neurology; Neurosurgery
- Web of Science ID
- WOS:000262016200006
- Scopus ID
- 2-s2.0-60749110095
- Other Identifier
- 991021933410604721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Clinical Neurology
- Surgery